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INTRODUCTION
Although diagnosis using electronic endoscopy
has undergone remarkable evolution, no new diagnostic
method for microcarcinoma utilizing electronic en-
doscopy has been developed (1). An accurate diagnosis
of small lesions by conventional endoscopy is difficult
in some cases, and it depends on the histopa-
thological findings of a biopsy specimen (2). To
obtain information on lesions that are not evident by
conventional endoscopy, various techniques have
been developed (2-5). Labeling of micro lesions with
an antibody detectable by electronic endoscopy,
followed by computer processing and imaging of the
electronic signals of the labeling substance, may allow
the diagnosis of such microcarcinomas. Fluorescent
labeling substances are highly sensitive. Several kinds
of labeling agents have been developed (6, 7), but
many of them fluoresce when exposed to ultraviolet
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rays which are likely to damage the DNA of living
tissues (8). Thus, we attempted to develop an infrared
fluorescence endoscopic method using an infrared
fluorescence-labeled antibody with less background
noise (9).
Indocyanine-green, which is known to emit fluo-
rescence in the infrared range (10), is used in fluo-
rescein angiography (11) to determine the depth
of burns (12), but it does not bind to an antibody.
Thus, we synthesized indocyanine-green-N-hydroxy-
succinimide ester (ICG-sulfo-OSu) which can bind
to a antibody (13), and developed an infrared fluo-
rescence microscope that can detect ICG-sulfo-OSu
(14, 15). Using this system, we investigated the
fluorescence characteristics of ICG-sulfo-OSu and
labeled antibody activity (16).
Then we immunostained paraffin-embedded sections
of human gastric cancer and excised fresh gastric
specimens with ICG-sulfo-OSu-labeled anti-human
CEA antibody (17). The infrared fluorescence was
found to correspond to the area stained with 3-3’
diaminobenzidine (DAB) (17, 18). These findings
indicated that microcarcinoma may be evidenced
by an infrared ray electronic endoscopy using ICG-
sulfo-OSu-labeled anti-human CEA antibody. However,
the infrared fluorescence intensity of ICG-sulfo-OSu
is not sufficient for imaging microcarcinomas (19,
20).
In an attempt to obtain a compound more appro-
priate for infrared fluorescence labeling, we synthesized
3-indocyanine-green-acyl-1, 3-thiazolidine-2-thione
(ICG-ATT)(21) and investigated the differences between
the optical characteristics of ICG-sulfo-OSu-labeled
and ICG-ATT-labeled antibodies (22). Diagnostic
methods using labeled antibodies have been reported
to detect specific signals from lesions, and to be of
diagnostic value (3, 7, 23-25). However, many aspects
regarding the binding of fluorescence-labeled anti-
bodies need to be elucidated to establish an accurate
diagnostic method. Details of the binding of ICG
derivatives to antibodies are also unknown, although
the possibility of non-covalent binding has been reported
in some cases (22). The ratio of non-covalent bonds
in labeled antibodies is thought to influence fluo-
rescence intensity and background noise (2). Fur-
thermore, the binding molar ratio of the labeling
substance to an antibody may also have a marked
influence on fluorescence intensity (24). Thus, we
investigated the binding of ICG derivatives to an
antibody, and the optimum binding molar ratio for
a labeled antibody.
MATERIALS AND METHODS
Materials
As an anti-MUC 1 antibody, MY. 1 E 12 provided
by Professor Irimura (Department of Cancer Biology
and Molecular Immunology, Faculty of Pharma-
ceutical Sciences, The University of Tokyo, Tokyo)
was used. Although this anti-MUC1 antibody reacts
with the normal mucosa (26), its sensitivity to cancer
tissue is high (27) and staining intensity was sig-
nificantly higher in cancer tissues than in non-
neoplastic tissues (28). Therefore, we thought it
may become a useful marker for the diagnosis of
microcarcinomas.
As for the labeling substances, the ICG derivatives
ICG-sulfo-OSu (DOJINDOLABORATORIES,Kumamoto,
Japan) and ICG-ATT were used. For paraffin-embedded
sections of human gastric cancer, surgical prepa-
rations of adenocarcinoma were used.
Equipment
Absorption of ultraviolet visible light and fluo-
rescence spectrum were measured using N, N-
dimethylformamide (DOJINDO LABORATORIES,
Kumamoto, Japan and BECKMAN DU 650 spec-
troscope, and 650-40 spectrophotometer (Hitachi
High-Technologies, Tokyo), respectively. The fluo-
rescence microscope, BX-60 (Olympus Optical Co.,
Ltd., Tokyo) with attached excitation and barrier
filters was used. An ICCD-500/DF camera (Hamamatsu
Photonics K.K., Hamamatsu, Japan), an EVIP-230
image capture system (OlympusOpticalCo., Ltd., Tokyo),
and a magneto-optic disc drive S321S (OlympusOptical
Co., Ltd., Tokyo) as the image recording system, were
used. For imaging infrared fluorescence, a reflected
illumination-type infrared fluorescence imaging system
(Olympus Optical Co., Ltd., Tokyo)(15) was used. This
system is composed of an infrared microscope, an
excitation filter with transmission wavelengths of 710-
790nm, a barrier filter with transmission wavelengths
of 810-920nm and a highly sensitive intensified charge-
coupled device (ICCD) camera.
The protein assay kit used to quantify protein was
purchased from Bio-Rad Co. (Hercules, CA). The PD-10
columnwas purchased fromAmershamBiosciencesK.K.
(Piscataway, NJ).
Methods
Labeling of the antibody and investigation of the
binding of the labeling substance to the antibody
The anti-MUC1 antibody MY. 1E12 was labeled
with ICG-sulfo-OSu and ICG-ATT to obtain two
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markers using a PD-10 column as previously reported
(13) and the absorbance was measured. To remove
the ICG derivative bound to the antibody by non-
covalent binding, ethylacetate was added to the labeled
antibody solution, followed by stirring at room
temperature protected from light for 30 minutes,
and the aqueous layer was collected. The absorbance
of the collected aqueous layer was measured. The
absorbance of the control solution before treatment
with ethylacetate was taken as 100% and the per-
centage of residual ICG derivative-labeled antibody
was calculated (Fig. 1, Method A).
Binding molar ratio of the labeling substance to theantibody
The ICG derivative was reacted with 1.57 mg/ml
anti-MUC1 antibody at 4, 8, 16, and 32molar equivalents,
and the protein content of the labeled antibody was
measured using a protein assay kit. Absorbance of
the labeled antibody was measured at the maximum
absorption wavelength and the content of the ICG
derivative-labeled anti-MUC 1 antibody was calculated
from the molar molecular extinction coefficient. The
binding molar ratio (F/P ratio) of the ICG derivative
to anti-MUC 1 antibodywas calculated from the above
values (Fig. 1, Method B). In addition, the fluorescence
intensity of each labeled antibody solutionwasmeasured
using a spectrophotometer.
Observation of infrared fluorescence in tissue sections
After deparaffinizing thin sections(2-3 µm)of human
gastric cancer in xylol, they were coveredwith normal
goat serum and allowed to react at room temperature
for 20 minutes to block non-specific binding. After
rinsing with 0.1 M phosphate buffered saline (PBS,
pH 7.2), ICG-ATT-and ICG-sulfo-OSu-labeled antibodies
were separately applied to two adjacent sections of
the same tissue, and allowed to react at room tem-
perature in a wet box for 90 minutes. The sections
were rinsed with PBS, mounted with glycerin, and
observed using a reflected illumination-type infrared
fluorescence imaging system(Olympus Optical Co., Ltd.)
(15). To keep a constant condition throughout the
observation, the laboratory was kept dark at room
temperature, not to affect the results. ICG-ATT-labeled
anti-MUC 1 antibody was dilutedwith PBS to investigate
its optimum concentration, and reacted with the
antibody at various concentrations(1,000, 500, 250,
and 125 mg/ml). As controls, the adjacent sections
were stained with hematoxylin and eosin (HE staining)
and immunostained according to the avidin-biotinylated
peroxidase complex (ABC) method using anti-MUC1
antibody.
Investigation of nonspecific reaction with ICG-ATT
To confirm whether the fluorescent images de-
tected in paraffin-embedded sections of human
gastric cancer using ICG-ATT-labeled anti-MUC 1
antibody were due to the antigen-antibody reaction,
a control experiment was performed. After tissue
sections were covered with unlabeled anti-MUC1
antibody and incubated at 4 overnight, ICG-ATT-
labeled anti-MUC 1 antibody was allowed to react
with the sections at room temperature for 90 minutes,
and fluorescent images were observed. The unla-
beled anti-MUC 1 antibody was diluted in PBS at
concentrations of 1,000, 500, 250 and 125 µg/ml. As
the control, normalmouse antiserumwas used similarly
and incubated at 4 overnight, followed by the reaction
of tissue sections with ICG-ATT-labeled anti-MUC 1
antibody, and the fluorescent images were evaluated.
RESULTS
Investigation of the binding of the labeling substance
to the antibody
The residual rates of the ICG derivative ICG-ATT
and ICG-sulfo-OSu, after acetate treatment were
67.5% and 65.0%, respectively, showing that covalent
binding accounted for nearly 70% of the bonds in either
derivative-labeled antibody. Almost no difference was
observed in the ratio of covalent bonds to all bonds
between the two ICG derivatives.
Binding molar ratio of the labeling substances to the
antibody (Table 1)
When 4, 8, and 16 molar equivalents of the ICG
derivativeswere used, the F/P ratios of ICG-ATT-labeled
Fig.1．Evaluation of the binding and binding molar ratios
between labeling compounds and antibody.
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fluorescent antibody were 2.94, 4.18, and 6.50, re-
spectively, and those of ICG-sulfo-OSu-labeled
fluorescent antibody were 1.50, 2.90, and 5.97, re-
spectively. In contrast, when 32 molar equivalents
were used, the F/P ratios of ICG-ATT- and ICG-sulfo-
OSu-labeled fluorescent antibodies were 6.75 and
10.9, respectively. However, the fluorescence intensity
of the ICG-ATT-labeled antibody was generally
lower than that of the ICG-sulfo-OSu-labeled antibody.
Furthermore, when the ICG-ATT reacted with anti-
MUC 1 antibody was doubled from 16 to 32 molar
equivalents, almost no change of the F/P ratio was
observed, but an increase of the F/P ratio propor-
tional to the increase in the equivalents of ICG-sulfo-
OSu was observed.
Observation of infrared fluorescence in tissue sections
When 1,000 and 500 µg/ml ICG-ATT-labeled anti-
MUC 1 antibody were used, distinct fluorescence
was observed in the cancerous area on the tissue
sections. When 250 µg/ml ICG-ATT-labeled anti-
MUC 1 antibody was used, the intensity of fluores-
cence of the cancerous tissue decreased, and the
image was slightly indistinct. When 125 µg/ml was
used, almost no fluorescence of the cancerous area
was observed. We used 6 tissue sections of 3 gastric
cancers, and the results were similar in all tissue
sections. There were no significant differences in the
fluorescence intensity observedwith 1000 and 500µg/ml
of ICG-ATT-labeled anti-MUC 1 antibody. Moreover,
no fluorescencewas observed in the normal areas of the
tissue sections. Based on these findings, fluorescence-
labeled antibody was used at 500 µg/ml for immu-
nohistochemical staining in the rest of the experi-
ments.
ICG-ATT-labeled antibodies with 4 different F/P
ratios were reacted with cancer tissue sections as
described above, and the fluorescence in the cancerous
area was examined. When ICG-ATT-labeled fluorescent
antibody with F/P ratios of 2.94 and 4.18 was used,
specific and distinct fluorescent images were observed
in the cancerous area of the tissue sections. In contrast,
when the F/P ratios were 6.50 and 6.75, the intensity
of fluorescence in the cancerous area decreased,
and the images were indistinct (Table 2 and Fig. 2).
When paraffin-embedded sections of tissues adjacent
to the gastric cancer were immunostained using
ICG-sulfo-OSu-labeled fluorescent antibody, fluo-
rescence was very weak compared to immunostaining
Table 1. Relationship between F/P ratio and fluorescence
intensity among all binding modes of ICG derivatives
ICG-derivative(mol eq.) F/P ratio Fluorescence intensity
ICG-ATT(4)
ICG-ATT(8)
ICG-ATT(16)
ICG-ATT(32)
ICG-sulfo-OSu(4)
ICG-sulfo-OSu(8)
ICG-sulfo-OSu(16)
ICG-sulfo-OSu(32)
2.94
4.18
6.50
6.75
1.50
2.90
5.97
10.9
14.5
17.4
56.8
69.6
24.8
40.8
125
200
Table 2. Relationship between F/P ratio and fluorescence
intensity on tissue sections.
ICG-derivative-labeled
MUC 1 antibody F/P ratio Fluorescent image
ICG-ATT-labeled
MUC 1 antibody
2.94
4.18
6.50
6.75
+++
+++
++
++
ICG-sulfo-OSu-labeled
MUC 1 antibody
1.5０
2.90
5.97
10.9
++
++
+
+
Fig. 2．Infrared fluorescent image of gastric cancer immunostained with ICG-ATT labeled MUC 1 antibody.
A : ICG-ATT/IgG=8 ; B : ICG-ATT/IgG=32. At an F/P ratio of 6.75 images were unclear.
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with ICG-ATT-labeled fluorescent antibody, and
nonspecific staining of the background was re-
markable (Fig. 3 A and B). The regions stained with
DAB by the ABCmethod and the fluorescent regions
stained with ICG-ATT-labeled antibody corresponded
with each other (Fig. 3 C). Figure 3 shows a tissue section
adjacent to the area shown in figure 2.
Investigation of nonspecific reaction with ICG-ATT
After pretreatment with unlabeled anti-MUC 1
antibody, tissue sections were reacted with ICG-ATT-
labeled MUC 1 antibody, and infrared fluorescence
was measured. When the tissue sections were pre-
treated with 1,000 or 500 µg/ml of unlabeled anti-
MUC 1 antibody, the fluorescence intensity decreased,
and no distinct fluorescent image was observed.
When the tissue sections were pretreated with 250
and 125 µg/ml of unlabeled anti-MUC 1 antibody, the
fluorescence intensity was strong. Distinct fluores-
cent images were also obtained when the sections
were pretreated with normal mouse antiserum
(Table 3 and Fig. 4 A-C). We used 6 tissue sections
of 3 gastric cancers, and the fluorescence results were
similar in all tissue sections. Control experiments on
adjacent sections were performed for all immunostained
sections. Fluorescence detection and imaging were
performed in the dark at the same room tempera-
ture, as already described.
Fig.3．Infrared fluorescent image of gastric cancer immunostained
with ICG-derivative labeled MUC 1 antibody.
A:ICG-ATT;B:ICG-sulfo-OSu, ICG derivative/IgG=8. The fluorescence
intensity of the antigen stained with the ICG-sulfo-OSu labeled antibody
was markedly lower than that stained with the ICG-ATT labeled
antibody. Nonspecific fluorescence was predominantly observed in
the background region with ICG-sulfo-OSu labeled antibody compared
with C stained according to the conventional ABC method using
DAB.
Table 3. Infrared fluorescence intensity according to the
proportion of labeled and unlabeled antibodies.
ICG-ATT-labeled
MUC 1 antibody(µg/ml)
Unlabeled MUC 1
antibody(µg/ml)
Infrared fluorescent
image
500
500
500
500
1000
500
250
125
-
-
+
++
500 Mouse lgG +++
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DISCUSSION
To date, several procedures using labeled antibodies
have been developed for the diagnosis of gastroin-
testinal carcinoma (3, 7, 23-25). These procedureswere
reported to be useful because lesion-specific signals
were obtained. However, the mode of binding between
the fluorescent compound and the antibody remains
unclear. Fluorescence in the field of infrared rays has
not been used in gastroenterology as yet (29). However,
the markedly low biological background noise in
the field of infrared rays may facilitate specific diagnosis,
differing from diagnostic procedures using auto-
fluorescence (9).
We have previously developed ICGderivatives that
can be used to label antibodies for infrared fluores-
cence imaging (13, 16). However, themode of binding
between those ICG derivatives and antibodies has
not been elucidated, although it was suggested that
the binding included non-covalent bonds. The results
of this study showed that covalent bonds accounted
for approximately 70% of all binding between anti-
bodies and ICG-ATT or ICG-sulfo-OSu. In addition,
the data shown in Table 3 demonstrate that fluo-
rescence observed on paraffin-embedded tissue
sections was produced by the reaction between
the labeled antibody and the antigen in the tissue.
However, in our previous study fluorescence intensity
was not sufficient to detect micro-lesions. It was
considered that fluorescence intensity decreased
due to the following reasons:(a) the fluorescent dye
itself bound or adhered to the antigen-binding site
(hyper-variable region) in the Fab region of the
antibody, or (b) the specificity of the antibody for
the antigen decreased during the procedure. This
was similar to when the binding of a fluorescent dye
changes the tertiary structure of an antibody. If a
fluorescent dye is electrically charged, the binding
of the fluorescent dye alters the entire electric charges
in fluorescent-labeled antibody. This may result in
nonspecific staining of areas other than the antigenic
region due to static electric binding and unclear
fluorescent images due to an antigen-antibody reaction.
If there is unlabeled fluorescent antibody, the binding
of the fluorescent-labeled antibody to the antigen
is competitively inhibited by the unlabeled antibody,
probably resulting in decreased fluorescence. Therefore,
it is important to calculate the binding molar ratio of
Fig.4．Infrared fluorescence intensity according to the proportion
of labeled and unlabeled antibodies.
A : 500 µg/ml of ICG-ATT labeled MUC 1 antibody and 1000 µg/
ml of unlabeled antibody ; B : 500 µg/ml of ICG-ATT labeled MUC
1 antibody and 250 µg/ml of unlabeled antibody ; C : 500 µg/ml of
ICG-ATT labeled MUC 1 antibody and mouse IgG. When the
tissue sections were pretreated with 250 µg/ml of unlabeled anti-
MUC1 antibody, or normal mouse antiserum, distinct fluorescent
images were also obtained.
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the fluorescent dye to the antibody (F/P ratio). The
decreased fluorescence intensity of the antigen cannot
be avoided when the F/P ratio is markedly high or
low. From this point of view, the labeling of the antibody
at an optimal F/P ratio is very important.
In this study, we compared ICG-sulfo-OSu and ICG-
ATT labeled antibodies regarding optical character-
istics, properties, and immunohistological staining
(16, 22). As for the optical characteristics of ICG-
ATT- and ICG-sulfo-OSu-labeled antibodies, the intensity
of fluorescence obtained with ICG-sulfo-OSu-labeled
antibody was stronger than that obtained with ICG-
ATT-labeled antibody at a uniform concentration of
the antibody. Actually, however, when these fluorescent
antibodies were reacted with the antigen on tissue
sections, results contrary to those expected based
on the fluorescence intensity of the labeled antibody
were obtained. Fluorescent images of gastric cancer
obtained with ICG-ATT-labeled antibody were far
clearer than those obtained with ICG-sulfo-OSu-
labeled antibody.
One plausible reason for this finding was that the
reduction of the MUC 1 antibody specificity may be
less when labeled with ICG-ATT than when using
ICG-sulfo-OSu. However, it remains unclear whether
this finding was due to differences in the absolute
number of fluorescent dye molecules bound to the
hyper-variable region of the antigen, to differences
in the alteration of the tertiary structure of the antibody
resulting from the binding to either ICG derivative,
or to other unknown factors.
Moreover, differences in nonspecific fluorescence
between ICG-ATT- and ICG-sulfo-OSu-labeled anti-
bodies might have influenced the reactivity of the
antigen (22). Since carbon chains bound to the
framework of ICG differ between ICG-ATT and ICG-
sulfo-OSu, the negatively charged terminal side chain
of ICG-sulfo-OSu (SO3-) alters all the electric charges
in the antibody. Subsequently, if static electricity enhances
nonspecific binding of the labeled antibody to sur-
rounding tissues, background tissues are nonspecifically
stained when the ICG-sulfo-OSu-labeled antibody
is used, probably resulting in decreased reactivity
due to the antigen-antibody reaction. In this study,
however, the results of conventional immunostaining
of tissue sections using fluorescent-labeled antibodies
did not show any significant differences in the level
of nonspecific staining of background tissues due
to differences in fluorescent labeling compounds or
F/P ratios. To investigate the cause of differences
in fluorescence intensity, experiments facilitating a
direct comparison of the numerically evaluated
specificity of fluorescent-labeled antibodies and the
degree of nonspecific fluorescence may be required
in the future. We used anti-MUC1 antibody in this
study, which is a tumor marker. More investigations
using different antibodies which show cross reactivity
with cancer tissues (e. g. anti - CEA antibody) are needed.
We presume that similar results should be obtained
because the basic structure of antibodies is similar.
It has been demonstrated that immunostaining
can be performed using both fresh specimens (30)
and in vivo (31) by distributing labeled antibodies.
Actually, a strict toxicity test is needed for ICG-
derivatives and labeled antibodies for in vivo use
because they are totally different from ICG. However,
the basic structures of ICG and ICG-derivatives are
similar, which may suggest low or no toxicity for
the living body.
In conclusion, it is quite likely that ICG-derivative-
labeled antibodies will become available for use in
clinical settings in the near future.
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